Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Stage III/IV Adult Diffuse Large Cell Lymphoma
- Stage III/IV Follicular Lymphoma
- Stage III/IV Mantle Cell Lymphoma
Interventions
- DRUG: Retroviral vector-transduced autologous T cells to express CD22-specific CARs
Sponsor
Xinqiao Hospital of Chongqing
Collaborators